This suggests that reduced striatal presynaptic dopamine transporter binding may serve as a biomarker for the pathogenesis of chorea independent of the etiology, however, these changes are reversible in transient causes of chorea while they are permanent in chronic/progressive causes of chorea. This evidence concerns the gene SLC6A3 and choreatic disease.